Medtronic To Face Class Action Suit From Canadian Users Of MiniMed Insulin Pumps
A national class action in Canada has been commenced against Medtronic Plc (NYSE:MDT) over its MiniMed 630G and 670G insulin pumps. Rochon…
The Daily Biotech Pulse: Moderna Gains On Vaccine News, Novartis Reports Q3 Beat, Adcom Reviews Authorization Of Pfizer-BioNTech’s Vaccine For Children
Here's a roundup of top developments in the biotech space over the last 24 hours:
Medtronic Warns On Percept PC Implantable Neurostimulators In Europe
Medtronic Plc (NYSE:MDT) has issued an urgent field safety notice in Europe to warn of its Percept PC Implantable Neurostimulator (INS)…
Medtronic Says Children Achieve Time In Range Mirroring Well-Controlled Adults For First Time In Real-World Study Of MiniMed 780G system
Medtronic plc (NYSE:MDT), a leading global healthcare technology company, recently announced one-year, real-world clinical data on 3,211 pediatric and adolescent patients with type 1 diabetes 15 years old and below using
Wells Fargo Maintains Overweight on Medtronic, Lowers Price Target to $144
Wells Fargo analyst Larry Biegelsen maintains Medtronic (NYSE:MDT) with a Overweight and lowers the price target from $151 to $144.
Health Care Sector Appears to Be a Drag on Positive UnitedHealth Earnings
Stock futures were pointing to a higher open even before Goldman Sachs (NYSE: GS) reported better than expected earnings.
Medtronic’s Hugo Surgical Robot Wins Regulatory Nod In Europe
Medtronic plc (NYSE:MDT) has secured European approval for its Hugo surgical robot. Hugo performed its first human procedure in June this…
Medtronic Hugo Robotic-Assisted Surgery System Receives European CE Mark Approval
Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received CE (Conformité Européenne) Mark for the Hugo™ robotic-assisted surgery (RAS) system,
10 Health Care Stocks With Unusual Options Alerts In Today’s Session
This unusual options alert can help traders track potentially big trading opportunities. Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Unusual trading activity could push option prices to hyperbolic or underperforming levels.